43 THORNDIKE STREET, CAMBRIDGE, MA
Amylyx Pharmaceuticals Enters Underwriting Agreement for 14.09M Shares
Investor Presentation
Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Reports Second Quarter 2026 Financial Results
Election of Class II Directors at Amylyx Pharmaceuticals Annual Meeting
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities